PALI PALISADE BIO INC

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand

Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced  of Palisade Bio, participated in the .

As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development.

The on-demand video webcast is now available on as well as the  page under the  section of the Company’s website ().

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
22/07/2025

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Adjournment of Special Meeting of Stockholders ...

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company’s special meeting of stockholders held on September 26, 2025 at 10:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A ...

September 26, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Adjournment of Special Meeting of Stockholders ...

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company’s special meeting of stockholders held on September 18, 2025 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A q...

September 18, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using FDA-defined endpoints Biomarker analyses showed normalization of 186 genes linked to fibrosis and Crohn’s disease strictures, supporting translational potential in fibrostenotic Crohn’s disease (FSCD) Patient dosing in the Phase 1b FSCD study is expected to begin in 2H 2025; Phase ...

September 17, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PA...

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD) First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND submissions in Q1 2026 Carlsbad, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therap...

September 5, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and...

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 – Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan  – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics – Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch